- SCOTT GARLAND President and Chief Executive Officer
- JOHN CURNUTTE, M.D., PH.D Executive Vice President, Research & Development
- MARDI C. DIER Executive Vice President, Chief Financial Officer
- ERNIE MEYER Executive Vice President, Chief Human Resources Officer
- JOHN MORIARTY Executive Vice President,
General Counsel and Secretary
GLENN BRAME Senior Vice President,
- JOHN H. (JACK)
LAWRENCE, M.D. Senior Vice President,
Chief Medical Officer
President and Chief Executive Officer
Mr. Garland joined Portola in October 2018 as president and chief executive officer. He brings more than two decades of broad executive leadership experience to Portola, including a strong track record driving multiple billion-dollar product launches.
Mr. Garland joined Portola from Relypsa, Inc., where he was president and previously chief commercial officer. During his tenure, Mr. Garland was responsible for the integration and growth of the U.S. operations after Relypsa was acquired by Vifor Pharma Group in 2016.
Prior to Relypsa, Mr. Garland was executive vice president and chief commercial officer of Exelixis, Inc., where he led global commercial operations and directed sales, marketing and market access in the United States. Previously, Mr. Garland spent close to a decade at Genentech leading full scale commercial franchises for two multi-billion dollar therapies – Avastin® (bevacizumab) and Rituxan® (rituximab). He started his career at Merck as a sales representative and then went on to serve at Amgen in various sales and marketing roles, including market development, to support the launch of Aranesp® (darbepoetin alfa).
Mr. Garland has a B.S. in biological sciences from California Polytechnic State University, San Luis Obispo, and an M.B.A. from Duke University’s Fuqua School of Business. Mr. Garland is a member of the Board of Directors for Karyopharm Therapeutics, a company focused on hematologic and oncology diseases.
JOHN T. CURNUTTE, M.D., Ph.D.
Executive Vice President, Research & Development
John Curnutte, M.D., joined Portola as executive vice president, research and development in 2011. Prior to joining Portola, Dr. Curnutte served as chief executive officer of 3-V Biosciences, a private start-up company founded in 2007 with the goal of developing host-directed antiviral small molecules. Before that, he served as president at Schering-Plough Biopharma (formerly DNAX Research Institute and now Merck Research Laboratories), where he led the drug discovery and early development efforts for biologic therapeutics. During his time with Schering-Plough, eight therapeutic entities progressed into development, including five small molecules and one gene therapy construct, in the immunology and oncology therapeutic areas. Earlier in his career, he held several senior management positions at Genentech during which he oversaw that company’s immunology discovery program. Prior to Genentech, Dr. Curnutte was a tenured faculty member at The Scripps Research Institute, pursuing basic and clinical research in inflammation biochemistry and the molecular genetics of congenital immune deficiencies.
Dr. Curnutte received an undergraduate degree in biochemistry and molecular biology from Harvard University and an M.D. and a Ph.D. in biological chemistry from Harvard Medical School. He is currently an adjunct clinical professor of pediatrics at Stanford University School of Medicine and a member of the medical staff, where he continues to consult on patients with primary immunodeficiencies. Dr. Curnutte is a member of the board of directors of diaDexus, Inc., a company focused on cardiovascular diagnostics.
MARDI C. DIER
Executive Vice President, Chief Financial Officer
Mardi Dier joined Portola in August 2006 as senior vice president and chief financial officer and has served as executive vice president and chief financial officer since November 2013. Ms. Dier is responsible for leading the corporate finance, accounting, information technology, global supply chain, investor relations and corporate communications functions. Ms. Dier brings to Portola nearly 20 years’ experience in the life sciences industry. During her tenure at Portola, she has successfully led a series of private, public and alternative financings. Previously, she served as vice president of investor relations at Chiron Corporation from 2003 until its acquisition by Novartis Pharmaceuticals in April 2006. Prior to joining Chiron, she served as a director in the West Coast investment banking practice at Prudential Securities, where she focused on client development, equity underwriting, and mergers and acquisitions for biotechnology and other life sciences companies. Ms. Dier began her finance career in the audit department of KPMG Peat Marwick.
She holds a B.S. in biology from Stanford University and an M.B.A. from the Anderson School at the University of California, Los Angeles. Ms. Dier is a member of the board of directors of Adamas Pharmaceuticals, Inc., a company focused on chronic neurological diseases.
Executive Vice President, Chief Human Resources Officer
Ernie Meyer joined Portola as executive vice president, chief human resources officer in 2018. In this role, Mr. Meyer is responsible for the development and execution of the global human resources strategy to drive and deliver on business results aligned with the company’s strategy, goals and values. He also serves as a member of Portola’s Executive Committee.
Mr. Meyer joins Portola from Celgene, where he spent more than 13 years in positions of increasing scope and responsibility. Most recently, Mr. Meyer served as executive vice president of human resources & corporate services, and played a significant role in the company’s growth and expansion from approximately 700 employees in two countries to more than 7,000 employees in 37 countries. His experience and expertise extend across the spectrum of human resources, including talent development, diversity and culture initiatives, new business integration, geographic expansions and innovative total rewards strategies. Prior to joining Celgene, Mr. Meyer held various global rewards leadership roles at Motorola and The Travelers Insurance Company.
Mr. Meyer holds a B.S. in Business Management with a concentration in Management Information Systems from Widener University.
Executive Vice President, General Counsel and Secretary
John B. Moriarty, Jr., J.D., joined Portola as executive vice president, general counsel and secretary in 2018. In this role, Mr. Moriarty serves as Portola’s chief legal officer, responsible for leading all legal, regulatory, governance and compliance initiatives. He is directly involved in strategic business transactions and corporate expansion as a member of Portola’s Executive Committee.
Prior to joining Portola, Mr. Moriarty was executive vice president, general counsel for Alexion Pharmaceuticals, where he was responsible for overseeing all global legal matters spanning 50 countries, as well as managing Alexion’s Global Government Affairs and Global Corporate Communications teams. Previously, he was senior vice president, general counsel and chief legal officer at Elan Corporation plc, and served as a member of Elan’s Executive Management team. Prior to Elan, Mr. Moriarty held positions of increasing responsibility and leadership at Amgen. Early in his career, Mr. Moriarty worked as an attorney in the healthcare practice of a national law firm’s Washington, DC and New York offices and was a healthcare fraud prosecutor in the U.S. Attorney’s Office and the Virginia Attorney General’s Office.
Mr. Moriarty holds a J.D. from the University of Georgia School of Law, cum laude, and a B.A. from the University of Virginia, with distinction. He has served on the board of trustees for the American Kidney Fund since 2015.
Senior Vice President, Technical Operations
Glenn Brame joined Portola as senior vice president of technical operations in 2018. In this role, Mr. Brame is responsible for leading the Company’s technical operations including process development, manufacturing, supply chain, quality assurance, and end-to-end process and platform optimization for Portola’s entire portfolio. He also serves as a member of Portola’s Executive Committee, contributing directly to global expansion efforts and related CMC activities.
Prior to joining Portola, Mr. Brame was vice president of supplier and contract manufacturing excellence for Genentech, where he was responsible for the transformation of quality, manufacturing, technical services and supply chain operations for both biologics and small molecule products. During his tenure, Mr. Brame also served as vice president of global product quality and helped lead the successful start-ups of two new biologic manufacturing sites in Oregon and Singapore, as well as manufacturing and quality assurance for the product approvals of Kadcyla® and Erivedge®.
Previously, Mr. Brame was senior vice president of technical development and operations, leading a team of 1,200 professionals for Chiron Corporation and, upon its acquisition, Novartis. Earlier in his career, Mr. Brame held positions of increasing responsibility and leadership at Baxter BioScience where he served as both general manager and quality site head for large scale manufacturing plants, including a green field biologic drug substance and drug product start-up site in Switzerland.
Mr. Brame holds a B.S. from North Carolina State University and an M.B.A. from Delta State University.
JOHN H. (JACK) LAWRENCE, M.D.
Senior Vice President, Chief Medical Officer
John H. (Jack) Lawrence, M.D., joined Portola as senior vice president, chief medical officer in 2017. Dr. Lawrence is responsible for leading all product development and clinical strategies. Prior to joining Portola, Dr. Lawrence was with Bristol-Myers Squibb (BMS), where he spent more than 18 years in positions of increasing responsibility in the company’s cardiovascular division. He was most recently vice president and cardiovascular therapeutic area head with responsibility for global clinical development and regulatory activities of the Factor Xa inhibitor, apixaban. He also provided strategic input into the discovery and early development efforts for BMS’ cardiovascular programs, including Phase 2 trials in heart failure and stroke prevention. Dr. Lawrence received his medical degree from the University of Virginia and completed his cardiology fellowship training at The Johns Hopkins University School of Medicine, where he later served as an associate professor.